FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. What is presented is a polypeptide containing two binding fragments presented by antibodies; the first of them binds to CD3e(epsilon) chain epitope of a human or a primate, other than a chimpanzee, particularly Callithrix jacchus, Saguinus oedipus and Saimiri sciureus; the second one - to EGFR, Her2/neu or IgE of a human or a primate, other than a chimpanzee, with the above CD3e epitope containing the amino acid sequence Gln-Asp-Gly-Asn-Glu. There are also disclosed a coding sequence of the nucleic acid, a vector, a host cell and a method for preparing the above peptide, as well as a pharmaceutical composition and using the polypeptide in preventing, treating or relieving a proliferative disease, a malignant disease or an immunological disorder.
EFFECT: invention provides the clinical improvement of T-cell redistribution and the enhanced safety profile.
17 cl, 8 tbl, 26 dwg, 26 ex
Title | Year | Author | Number |
---|---|---|---|
CD3-EPSILON-BINDING DOMAIN HAVING INTERSPECIES SPECIFICITY | 2008 |
|
RU2561457C2 |
PSMA×CD3 BISPECIFIC SINGLE-CHAIN ANTIBODY HAVING INTERSPECIES SPECIFICITY | 2009 |
|
RU2559531C2 |
PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALIN XCD3, EPCAMXCD3, IGF-1RXCD3 OR FAP-ALPHA XCD3 BISPECIFIC SINGLE-CHAIN ANTIBODY WITH INTER-SPECIES SPECIFICITY | 2009 |
|
RU2547600C2 |
BISPECIFIC SINGLE-CHAIN ANTIBODY TO PSMAxCD3 WITH INTERSPECIES SPECIFICITY | 2011 |
|
RU2617942C2 |
BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
CD3-EPSILON-BINDING DOMAIN WITH INTERSPECIFIC SPECIFICITY | 2008 |
|
RU2769948C2 |
BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE | 2012 |
|
RU2605390C2 |
BISPECIFIC ASYMMETRIC HETERODIMERS COMPRISING ANTI-CD3 CONSTRUCTS | 2013 |
|
RU2650868C2 |
CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
Authors
Dates
2014-12-20—Published
2008-04-03—Filed